Top

Published in:

Open Access 01-12-2016 | Case report

The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children

Authors: Rachel F. Power, Barry Linnane, Ruth Martin, Noelle Power, Peig Harnett, Brian Casserly, Nuala H. O’Connell, Colum P. Dunne

Published in: BMC Pulmonary Medicine | Issue 1/2016

Abstract

Background

Burkholderia contaminans is an emerging pathogen in the cystic fibrosis (CF) setting. Included in the Burkholderia cepacia complex (Bcc), B. contaminans is a Gram negative, motile, obligate aerobe previously classified as a pseudomonad. Previous reports have described B. contaminans isolation from patients in Portugal, Switzerland, Spain, Argentina and the USA. This, however, is the first report relating to B. contaminans affecting Irish patients with CF, initially detected in a paediatric setting.

Case presentation

Burkholderia contaminans was identified in the routine analysis of sputum from a fourteen year old boy, at his annual review and subsequently from the sputum from his 19 year old brother. RecA gene sequencing and pulsed field gel electrophoresis (PFGE) were unable to distinguish between the isolates, which demonstrated with susceptibility to ciprofloxacin, cotrimoxazole, meropenem, pipercillin/tazobactam and ceftazidime. Both isolates were resistant to aztreonam, with reduced susceptibility to tobramycin. Following treatment with intravenous meropenem and ceftazidime, oral ciprofloxacin and nebulised tobramycin for 6 weeks, sputum specimens from both patients were negative for B. contaminans. No other member of the local CF cohort proved positive.

Conclusions

Bcc bacteria are associated with poor prognosis in CF and decreased life expectancy, specifically leading to a more rapid decline in lung function and, in some cases, to a fatal necrotizing pneumonia known as the “cepacia syndrome”. Some species exhibit innate resistance to multiple antimicrobial agents and their transmission rate can be high in susceptible patients. In that context, we describe the first incidence of CF-related B. contaminans in Ireland and its successful eradication from two patients, one paediatric, using an aggressive antimicrobial regimen.

Mahenthiralingam E, Urban TA, Goldberg JB. The multifarious, multireplicon Burkholderia cepacia complex. Nat Rev Microbiol. 2005;3(2):144–56.CrossRefPubMed

Vandamme P, Dawyndt P. Classification and identification of the Burkholderia cepacia complex: past, present and future. Syst Appl Microbiol. 2011;34(2):87–95.CrossRefPubMed

Venter JC, Remington K, Heidelberg JF, Halpern AL, Rusch D, Eisen JA, Wu D, Paulsen I, Nelson KE, Nelson W, et al. Environmental genome shotgun sequencing of the Sargasso Sea. Science. 2004;304(5667):66–74.CrossRefPubMed

Mahenthiralingam E, Baldwin A, Drevinek P, Vanlaere E, Vandamme P, LiPuma JJ, Dowson CG. Multilocus sequence typing breathes life into a microbial metagenome. PLoS One. 2006;1:e17.CrossRefPubMedPubMedCentral

Bloodworth RA, Selin C, Lopez De Volder MA, Drevinek P, Galanternik L, Degrossi J, Cardona ST. Draft genome sequences of Burkholderia contaminans, a Burkholderia cepacia complex species that is increasingly recovered from cystic fibrosis patients. Genome Announc. 2015;3(4):e00766-15

Martina P, Bettiol M, Vescina C, Montanaro P, Mannino MC, Prieto CI, Vay C, Naumann D, Schmitt J, Yantorno O, et al. Genetic diversity of Burkholderia contaminans isolates from cystic fibrosis patients in Argentina. J Clin Microbiol. 2013;51(1):339–44.CrossRefPubMedPubMedCentral

Barrado L, Martinez MT, Villa J, Orellana MA, Viedma E, Chaves F. Clonal diversity among Burkholderia cepacia complex isolates from cystic fibrosis patients in a reference unit. Enferm Infecc Microbiol Clin. 2013;31(10):665–8.CrossRefPubMed

Coutinho CP, Dos Santos SC, Madeira A, Mira NP, Moreira AS, Sa-Correia I. Long-term colonization of the cystic fibrosis lung by Burkholderia cepacia complex bacteria: epidemiology, clonal variation, and genome-wide expression alterations. Front Cell Infect Microbiol. 2011;1:12. doi:10.3389/fcimb.2011.00012. eCollection 2011.

Peterson AE, Chitnis AS, Xiang N, Scaletta JM, Geist R, Schwartz J, Dement J, Lawlor E, Lipuma JJ, O'Connell H, et al. Clonally related Burkholderia contaminans among ventilated patients without cystic fibrosis. Am J Infect Control. 2013;41(12):1298–300.CrossRefPubMed

10.

Coutinho CP, Barreto C, Pereira L, Lito L, Melo Cristino J, Sa-Correia I. Incidence of Burkholderia contaminans at a cystic fibrosis centre with an unusually high representation of Burkholderia cepacia during 15 years of epidemiological surveillance. J Med Microbiol. 2015;64(8):927–35.CrossRefPubMed

11.

Medina-Pascual MJ, Valdezate S, Carrasco G, Villalon P, Garrido N, Saez-Nieto JA. Increase in isolation of Burkholderia contaminans from Spanish patients with cystic fibrosis. Clin Microbiol Infect. 2015;21(2):150–6.CrossRefPubMed

12.

Martin M, Christiansen B, Caspari G, Hogardt M, von Thomsen AJ, Ott E, Mattner F. Hospital-wide outbreak of Burkholderia contaminans caused by prefabricated moist washcloths. J Hosp Infect. 2011;77(3):267–70.CrossRefPubMed

13.

Ohji G, Ohkusu K, Toguchi A, Otsuka Y, Hosokawa N, Iwata K. Burkholderia contaminans: unusual cause of biliary sepsis. J Infect Chemother. 2013;19(5):969–71.CrossRefPubMed

14.

Moehring RW, Lewis SS, Isaacs PJ, Schell WA, Thomann WR, Althaus MM, Hazen KC, Dicks KV, Lipuma JJ, Chen LF, et al. Outbreak of bacteremia due to Burkholderia contaminans linked to intravenous fentanyl from an institutional compounding pharmacy. JAMA Intern Med. 2014;174(4):606–12.CrossRefPubMed

15.

Farrell PM. The prevalence of cystic fibrosis in the European Union. J Cyst Fibros. 2008;7(5):450–3.CrossRefPubMed

16.

Cesarini S, Bevivino A, Tabacchioni S, Chiarini L, Dalmastri C. RecA gene sequence and Multilocus sequence typing for species-level resolution of Burkholderia cepacia complex isolates. Lett Appl Microbiol. 2009;49(5):580–8.CrossRefPubMed

17.

Minan A, Bosch A, Lasch P, Stammler M, Serra DO, Degrossi J, Gatti B, Vay C, D'Aquino M, Yantorno O, et al. Rapid identification of Burkholderia cepacia complex species including strains of the novel Taxon K, recovered from cystic fibrosis patients by intact cell MALDI-ToF mass spectrometry. Analyst. 2009;134(6):1138–48.CrossRefPubMed

18.

Carleton A, Casserly B, Power L, Linnane B, O’flaherty G, Powell J, Hartnett P, Collins J, Murphy P, Kenna D, et al. Clustered multidrug-resistant Bordetella petrii in adult cystic fibrosis patients in Ireland: case report and review of antimicrobial therapies. JMM Case Reports 2014;1(1).

19.

Mahenthiralingam E, Vandamme P, Campbell ME, Henry DA, Gravelle AM, Wong LT, Davidson AG, Wilcox PG, Nakielna B, Speert DP. Infection with Burkholderia cepacia complex genomovars in patients with cystic fibrosis: virulent transmissible strains of genomovar III can replace Burkholderia multivorans. Clin Infect Dis. 2001;33(9):1469–75.CrossRefPubMed

20.

Hall CM, Busch JD, Shippy K, Allender CJ, Kaestli M, Mayo M, Sahl JW, Schupp JM, Colman RE, Keim P, et al. Diverse Burkholderia species isolated from soils in the Southern United States with no evidence of B. pseudomallei. PLoS One. 2015;10(11):e0143254.CrossRefPubMedPubMedCentral

21.

da Silva K, Cassetari Ade S, Lima AS, De Brandt E, Pinnock E, Vandamme P, Moreira FM. Diazotrophic Burkholderia species isolated from the Amazon region exhibit phenotypical, functional and genetic diversity. Syst Appl Microbiol. 2012;35(4):253–62.CrossRefPubMed

22.

Nannini EC, Ponessa A, Muratori R, Marchiaro P, Ballerini V, Flynn L, Limansky AS. Polyclonal outbreak of bacteremia caused by Burkholderia cepacia complex and the presumptive role of ultrasound gel. Braz J Infect Dis. 2015;19(5):543–5.CrossRefPubMed

23.

Fehlberg LC, Andrade LH, Assis DM, Pereira RH, Gales AC, Marques EA. Performance of MALDI-ToF MS for species identification of Burkholderia cepacia complex clinical isolates. Diagn Microbiol Infect Dis. 2013;77(2):126–8.CrossRefPubMed

24.

Deng P, Wang X, Baird SM, Showmaker KC, Smith L, Peterson DG, Lu S. Comparative genome-wide analysis reveals that Burkholderia contaminans MS14 possesses multiple antimicrobial biosynthesis genes but not major genetic loci required for pathogenesis. Microbiologyopen. 2016. doi:10.1002/mbo3.333.PubMedPubMedCentral

25.

Araujo R, Caramalho R, Coutinho C, Sa-Correia I. SNaPBceBcon: a practical tool for identification and genotyping of Burkholderia cepacia and Burkholderia contaminans. J Clin Microbiol. 2016;54(2):483-8. doi:10.1128/JCM.02476-15. Epub 2015 Dec 9.

26.

Ferreira AS, Silva IN, Fernandes F, Pilkington R, Callaghan M, McClean S, Moreira LM. The tyrosine kinase BceF and the phosphotyrosine phosphatase BceD of Burkholderia contaminans are required for efficient invasion and epithelial disruption of a cystic fibrosis lung epithelial cell line. Infect Immun. 2015;83(2):812–21.CrossRefPubMed

27.

Lu SE, Novak J, Austin FW, Gu G, Ellis D, Kirk M, Wilson-Stanford S, Tonelli M, Smith L. Occidiofungin, a unique antifungal glycopeptide produced by a strain of Burkholderia contaminans. Biochemistry. 2009;48(35):8312–21.CrossRefPubMedPubMedCentral

28.

Gu G, Smith L, Liu A, Lu SE. Genetic and biochemical map for the biosynthesis of occidiofungin, an antifungal produced by Burkholderia contaminans strain MS14. Appl Environ Microbiol. 2011;77(17):6189–98.CrossRefPubMedPubMedCentral

29.

Ellis D, Gosai J, Emrick C, Heintz R, Romans L, Gordon D, Lu SE, Austin F, Smith L. Occidiofungin’s chemical stability and in vitro potency against Candida species. Antimicrob Agents Chemother. 2012;56(2):765–9.CrossRefPubMedPubMedCentral

30.

Lupo A, Isis E, Tinguely R, Endimiani A. Clonality and antimicrobial ausceptibility of Burkholderia cepacia complex isolates collected from cystic fibrosis patients during 1998–2013 in Bern, Switzerland. New Microbiol. 2015;38(2):281–8.PubMed

Title: The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children
Authors: Rachel F. Power
Barry Linnane
Ruth Martin
Noelle Power
Peig Harnett
Brian Casserly
Nuala H. O’Connell
Colum P. Dunne
Publication date: 01-12-2016
Publisher: BioMed Central
Published in: BMC Pulmonary Medicine / Issue 1/2016
Electronic ISSN: 1471-2466
DOI: https://doi.org/10.1186/s12890-016-0219-z

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

The first reported case of Burkholderia contaminans in patients with cystic fibrosis in Ireland: from the Sargasso Sea to Irish Children

Abstract

Background

Case presentation

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Background

Case presentation

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2016

Extra corporeal membrane oxygenation to facilitate lung protective ventilation and prevent ventilator-induced lung injury in severe Pneumocystis pneumonia with pneumomediastinum: a case report and short literature review

Pulmonary arterial hypertension in adult onset Still’s disease: a case report of a severe complication

Can fiberoptic bronchoscopy be applied to critically ill patients treated with noninvasive ventilation for acute respiratory distress syndrome? Prospective observational study

The significance of oral streptococci in patients with pneumonia with risk factors for aspiration: the bacterial floral analysis of 16S ribosomal RNA gene using bronchoalveolar lavage fluid

Can severe asthmatic patients achieve asthma control? A systematic approach in patients with difficult to control asthma followed in a specialized clinic

Pediatric cardiorespiratory failure successfully managed with venoarterial-venous extracorporeal membrane oxygenation: a case report

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page